Novartis' Bexsero gains 'breakthrough' status; BLA expected Q2
This article was originally published in Scrip
Executive Summary
Novartis revealed on 7 April that it has snagged its fourth FDA breakthrough therapy designation – this time for the firm's experimental meningitis B vaccine Bexsero (meningococcal group B vaccine [rDNA, component, adsorbed]).